Epsilon M&A Deal Report - Retrogenix

Transaction Multiples for the Valuation of Private Companies

Charles River Discovery Research Services UK > Retrogenix

Announced Date : 31 March 2021

Type : Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Charles River Discovery Research Services UK

Target: Retrogenix

Target Country: United Kingdom

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Retrogenix operates an early-stage contract research organisation (CRO ...

No EMAT : 114147

Transaction multiples available

EV/Sales EV/Gross Profit EV/EBITDA EV/EBIT Eq/PBT P/E Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating **

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1226

Example of comparable transactions on EMAT (same sub-sector):

Date Acquirer Target Country Multiples See details
18/07/2023 Groupe Vabel Laboratoires Sarbec France 0
24/04/2020 Orifarm Group Takeda Pharmaceutical's OTC and prescription pharmaceutical products in Europe Europe 0

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report
About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Sign up (free) to receive by e-mail updates on EMAT reports published on your preferred sector.

Subscribe to EMAT database